PTPRG and chronic myelogenous leukemia, BCR-ABL1 positive: We analyzed the modulation of CML cell model K562 transcriptome following transfection with the tumor suppressor gene PTPRG and treatment with the tyrosine kinase inhibitor (TKI) Imatinib with the aim of identifying genes responding to the PTPRG modulation and/or treatments with Imatinib.